Janux Therapeutics (NASDAQ:JANX) Shares Down 4.5%

Janux Therapeutics, Inc. (NASDAQ:JANX)’s share price fell 4.5% during trading on Friday . The stock traded as low as $32.66 and last traded at $32.80. 732 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 228,779 shares. The stock had previously closed at $34.35.

Several brokerages have commented on JANX. Evercore ISI began coverage on shares of Janux Therapeutics in a research report on Tuesday, July 6th. They issued an “outperform” rating and a $35.00 price target on the stock. Bank of America began coverage on shares of Janux Therapeutics in a research report on Tuesday, July 6th. They issued a “buy” rating and a $35.00 price target on the stock. Zacks Investment Research cut shares of Janux Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, September 9th. HC Wainwright initiated coverage on Janux Therapeutics in a report on Tuesday, July 6th. They set a “buy” rating and a $35.00 price objective on the stock. Finally, Cowen initiated coverage on Janux Therapeutics in a report on Tuesday, July 6th. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $35.00.

The business has a 50-day moving average of $30.09.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Tuesday, August 10th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.48). On average, sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.02 EPS for the current year.

Several hedge funds have recently modified their holdings of JANX. Royal Bank of Canada acquired a new position in shares of Janux Therapeutics during the second quarter worth approximately $32,000. Bank of America Corp DE acquired a new position in shares of Janux Therapeutics during the second quarter worth approximately $52,000. Qube Research & Technologies Ltd acquired a new position in shares of Janux Therapeutics during the second quarter worth approximately $357,000. Geode Capital Management LLC acquired a new position in shares of Janux Therapeutics during the second quarter worth approximately $549,000. Finally, Vanguard Group Inc. acquired a new position in shares of Janux Therapeutics during the second quarter worth approximately $723,000. Institutional investors own 59.46% of the company’s stock.

About Janux Therapeutics (NASDAQ:JANX)

Janux Therapeutics, Inc, a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.

Featured Article: What is a blue-chip stock?

Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.